In order to prepare the next generation of IBD drugs, Enterome is leading a discovery program of novel products originating from the gut microbiome with its high throughput discovery platform. Metagenomic/genomic libraries have been developed to identify active commensal derived molecules with regulatory functions and among them, new compounds for therapeutic purpose or new targets/pathways for drug discovery programs.
EB110 + EB120
Our lead discovery projects have identified unknown bacterial strains intimately correlated to clinical phenotypes. We are now in the process of functionally identifying microbiome-derived molecules and characterizing some hits by a deconvolution strategy, screened on various cellular assays and readouts.
EB110 is a metabolite secreted by a newly discovered bacteria identified by Enterome as being associated with the development of Crohn’s disease. It could become the first therapeutic attempt to inhibit immune reaction against the gut microbiome and block the evolution of Crohn’s disease. EB120 is a discovery program developed in the fields of Ulcerative Colitis (UC) and Irritable Bowel Syndrome (IBS). EB110 and EB120 are in early preclinical development in collaboration with two Pharmaceutical partners.
We have identified these products on our drug discovery platform which is unique regarding the fact that it integrates state of the art pharmaceutical industry process (used classically for small compounds library screen) with process especially implemented to deal with, and prepare large number of bacterial extracts.